ABSTRACT
Aim A high-throughput method using inductively coupled plasma mass spectrometry (ICP-MS) was developed and validated for the quantitative analysis of antimony in human plasma and peripheral blood mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis undergoing treatment with meglumine antimoniate.
Methods For this study, antimony was digested in clinical samples with 1% TMAH / 1% EDTA and indium was used as internal standard. Calibration curves for antimony, over the range of 25 to 10000 ng/mL were fitted to a linear model using a weighting of 1/concentration2. Accuracy, precision and stability were evaluated.
Results Taking the lower limit of quantitation (LLOQ) to be the lowest validation concentration with precision and accuracy within 20% (25% at the LLOQ), the current assay was successfully validated from 25 to 10000 ng/mL for antimony in human plasma and PBMCs. Dilution studies demonstrated that concentrations up to 100000 ng/mL of antimony in plasma were reliably analyzed when diluted into the calibration range.
Conclusion This protocol will serve as a baseline for future analytical designs, aiming to provide a reference method to allow inter-study comparisons.
What is already known about this subjectAntimonial drugs are the mainstay treatment for cutaneous leishmaniasis of which systemically administered pentavalent antimonials (SbV) are widely used, however the pharmacokinetics (PK) of these drugs at the site of action is unknown.
A wide range of analytical strategies have been used to quantify antimony in biological samples and atomic absorption spectroscopy is the most employed technique, however, no standardized methods for determination of intracellular concentrations of antimony were available.
Relationships between plasma and intracellular drug concentrations remain unknown for most antiparasitic drugs, and PK studies rely on plasma drug concentrations assuming these act as surrogates of intracellular concentrations.
We have developed and validated a reproducible and accurate ICP-MS method for the quantification of total antimony in human plasma and peripheral blood mononuclear cells (PBMCs) in accordance with the European Bioanalysis Forum (EBF) recommendations.
This method was successfully used to compare pharmacokinetic curves of antimony in plasma and intracellular compartments, in samples collected from patients undergoing treatment for cutaneous leishmaniasis with meglumine antimoniate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research reported in this publication was supported by Wellcome Trust 107595/Z/15/Z.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and monitored by CIDEIM ethics committee in accordance with national (resolution 8430, Republica de Colombia, Ministry of Health, 1993) and international (Declaration of Helsinki and amendments, World Medical Association, Fortaleza, Brasil, October 2013) guidelines
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors confirm that the Principal Scientific Investigator for this paper was Maria Adelaida Gómez and that the Principal Medical Investigator was Miguel Dario Prieto and that he had direct clinical responsibility for patients.
Data Availability
All data are included within the main manuscript file
